| REVIEWS |
|
|
|
|
|
Exploring the role of natural bioactive molecules in genitourinary cancers: how far has research progressed? |
| Fahadul Islam1, Nikhil Nath2, Mehrukh Zehravi3, Jishan Khan2, Sumiya Ben-Ta Jashim2, Manoj Shrawan Charde4, Rita Dadarao Chakole4, K. Praveen Kumar5, A. Kishore Babu6, Firzan Nainu7, Sharuk L. Khan8, Safia Obaidur Rab9, Talha Bin Emran1,10, Polrat Wilairatana11 |
1. Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, 1207, Bangladesh;
2. Department of Pharmacy, International Islamic University Chittagong, Kumira, Chittagong, 4318, Bangladesh;
3. Department of Clinical Pharmacy, College of Dentistry & Pharmacy, Buraydah Private Colleges, Buraydah, 51418, Kingdom of Saudi Arabia;
4. Government College of Pharmacy, Vidyanagar, Karad, Satara, 415124, Maharashtra, India;
5. Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Govt. of NCT of Delhi, Delhi Pharmaceutical Sciences and Research University (DPSRU), Mehrauli-Badarpur Road, PushpVihar, Sector 3, New Delhi, 110017, India;
6. Ratnadeep College of Pharmacy, Ratnapur, Jamkhed, Ahmednagar, 413206, Maharashtra, India;
7. Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, 90245, Indonesia;
8. Department of Pharmaceutical Chemistry, N. B. S. Institute of Pharmacy, Ausa, 413520, Maharashtra, India;
9. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia;
10. Department of Pathology and Laboratory Medicine, Warren Alpert Medical School & Legorreta Cancer Center, Brown University, Providence, RI, 02912, USA;
11. Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand |
|
|
|
|
Abstract The primary approaches to treat cancerous diseases include drug treatment, surgical procedures, biotherapy, and radiation therapy. Chemotherapy has been the primary treatment for cancer for a long time, but its main drawback is that it kills cancerous cells along with healthy ones, leading to deadly adverse health effects. However, genitourinary cancer has become a concern in recent years as it is more common in middle-aged people. So, researchers are trying to find possible therapeutic options from natural small molecules due to the many drawbacks associated with chemotherapy and other radiation-based therapies. Plenty of research was conducted regarding genitourinary cancer to determine the promising role of natural small molecules. So, this review focused on natural small molecules along with their potential therapeutic targets in the case of genitourinary cancers such as prostate cancer, renal cancer, bladder cancer, testicular cancer, and so on. Also, this review states some ongoing or completed clinical evidence in this regard.
|
| Keywords
Genitourinary cancers
Apoptosis
Urinary tract
Chemotherapy
Polyphenols
|
| Fund:The authors thank the Deanship of Scientifc Research at King Khalid Univer- sity for funding this work through the Large Research Group Project under grant number RGP.02/339/44. |
|
Corresponding Authors:
Mehrukh Zehravi,E-mail:mahrukh.zehravi@hotmail.com;Talha Bin Emran,E-mail:talhabmb@bgctub.ac.bd;Polrat Wilairatana,E-mail:polrat.wil@mahidol.ac.th
E-mail: mahrukh.zehravi@hotmail.com;talhabmb@bgctub.ac.bd;polrat.wil@mahidol.ac.th
|
|
Issue Date: 03 November 2023
|
|
|
[1] Penticuff JC, Woolbright BL, Sielecki TM, Weir SJ, Taylor JA III. MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential. Nat Rev Urol. 2019;16:318-28.
[2] Zarrabi K, Paroya A, Wu S. Emerging therapeutic agents for genitourinary cancers. J Hematol Oncol. 2019;12:1-25.
[3] Lenis AT, Lec PM, Chamie K. Bladder cancer: a review. JAMA. 2020;324:1980-91.
[4] Letašiová S, Medved'ová A, Šovčíková A, Dušinská M, Volkovová K, Mosoiu C, Bartonová A. Bladder cancer, a review of the environmental risk factors. Environ Heal. 2012;11:1-5.
[5] Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. Bladder cancer. Nat Rev Dis Prim. 2017;3:1-19.
[6] Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63.
[7] Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 2000;14:2410-34.
[8] Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36:1341-53.
[9] Jacqmin D, Van Poppel H, Kirkali Z, Mickisch G. Renal cancer. Eur Urol. 2001; 39.
[10] Störkel S, Van Den Berg E. Morphological classification of renal cancer. World J Urol. 1995;13:153-8.
[11] Thomas A, Necchi A, Muneer A, Tobias-Machado M, Tran ATH, Van Rompuy A-S, Spiess PE, Albersen M. Penile cancer. Nat Rev Dis Prim. 2021;7:11.
[12] Burgers JK, Badalament RA, Drago JR. Penile cancer: clinical presentation, diagnosis, and staging. Urol Clin North Am. 1992;19:247-56.
[13] Farrell MR, Xu JT, Vanni AJ. Current perspectives on the diagnosis and management of primary urethral cancer: a systematic review. Res Reports Urol. 2021; 325-334.
[14] Srinivas V, Khan SA. Female urethral cancer—an overview. Int Urol Nephrol. 1987;19:423-7.
[15] Leitzmann MF. Physical activity and genitourinary cancer prevention. Phys Act Cancer. 2011; 43-71.
[16] Morrison BF. Risk factors and prevalence of penile cancer. West Indian Med J. 2014;63:559-60.
[17] Gottlieb J, Higley C, Sosnowski R, Bjurlin MA. Smoking-related genitourinary cancers: a global call to action in smoking cessation. Rev Urol. 2016;18:194.
[18] Chandradas S, Skillin CB, Frenette CT. Hepatocellular carcinoma: metastatic disease. In: Introduction to cancer metastasis. USA: Academic Press; 2017. p. 163-75.
[19] Islam F, Mitra S, Emran TB, Khan Z, Nath N, Das R, Sharma R, Awadh AAA, Park MN, Kim B. Natural small molecules in gastrointestinal tract and associated cancers: molecular insights and targeted therapies. Molecules. 2022;27:5686. https://doi.org/10.3390/molecules27175686.
[20] Islam MR, Islam F, Nafady MH, Akter M, Mitra S, Das R, Urmee H, Shohag S, Akter A, Chidambaram K, et al. Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint. Molecules. 2022;27:2165. https://doi.org/10.3390/molecules27072165.
[21] Tang G-X, Wang Z-S, Liu D-G, Liu S-S. Gastroesophageal anastomotic leakage following resection of carcinoma of the esophagus and gastric cardia: analysis of ten cases. J Surg Oncol. 1990;43:50-2. https://doi.org/10.1002/jso.2930430113.
[22] Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Vareki SM, Pal SK, Sfanos KS. The microbiome and genitourinary cancer: a collaborative review. Eur Urol. 2019;75:637-46.
[23] Moore MJ, O’Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol. 1988;6:1736-45.
[24] Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, Zhong J, Zeng J. Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol. 2018;8:167.
[25] Gallagher DJ, Feifer A, Coleman JA. Genitourinary cancer predisposition syndromes. Hematol Clin. 2010;24:861-83.
[26] Cartwright RA. Bladder cancer screening in the United Kingdom. J Occup Med. 1990; 878-880.
[27] Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. JNCI J Natl Cancer Inst. 1994;86:1600-8.
[28] Bruyninckx R, Buntinx F, Aertgeerts B, Van Casteren V. The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice. Br J Gen Pract. 2003;53:31-5.
[29] Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med. 2009;133:1033-40.
[30] Hanna NH, Einhorn LH. Testicular cancer—discoveries and updates. N Engl J Med. 2014;371:2005-16.
[31] Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: a study of world war II veteran twins. Prostate. 1997;33:240-5.
[32] Cooney KA, Huang L, Sandler HM, Lange E, Lange K, Miesfeldt S, McCarthy JD, Montie JE, Oesterling JE. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst. 1997;89:955-9.
[33] Bluemn E, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012;24:251.
[34] Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730.
[35] Hinata N, Fujisawa M. Racial differences in prostate cancer characteristics and cancer-specific mortality: an overview. World J Mens Health. 2022;40:217.
[36] Kobayashi H, Tsuchiyama K, Taga M, Tokunaga T, Ito H, Yokoyama O. Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patients. Medicine (Baltimore). 2021; 100.
[37] Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-24.
[38] Miyao N, Naito S, Ozono S, Shinohara N, Masumori N, Igarashi T, Nakao M, Tsushima T, Senga Y, Horie S. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the japanese society of renal cancer. Urology. 2011;77:379-84.
[39] Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530.
[40] Hussain MHA, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial. J Clin Oncol. 2007;25:2218-24.
[41] Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006. Cancer. 2008;113:293-301.
[42] Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised. Double-blind phase iii trial. Lancet. 2007;370:2103-11.
[43] Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005) a benchmark for emerging targeted cancer therapies. Cancer. 2008;113:2457-63.
[44] Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer (Cochrane Review). J Am Coll Surg. 2005;200:A38-9.
[45] Golijanin DJ, Kakiashvili D, Madeb RR, Messing EM, Lerner SP. Chemoprevention of bladder cancer. World J Urol. 2006;24:445-72.
[46] Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404-23.
[47] Shin JH, Lim JS, Jeon BH. Pathophysiology of bladder cancer. Bl. Cancer 2018; 33-41. https://doi.org/10.1016/B978-0-12-809939-1.00003-5.
[48] Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778-92.
[49] Griffiths TRL. Cancer A. on B. Current perspectives in bladder cancer management. Int J Clin Pract. 2013;67:435-48.
[50] Almeida TC, da Silva GN. Resveratrol effects in bladder cancer: a mini review. Genet Mol Biol. 2021;44: e20200371.
[51] Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemo-preventive agents. Med Princ Pract. 2016;25:41-59.
[52] Rozengurt E. Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr Opin Oncol. 1999;11:116.
[53] Sun Y, Liu Y, Ma X, Hu H. The influence of cell cycle regulation on chemotherapy. Int J Mol Sci. 2021;22:6923.
[54] Mitra AP, Hansel DE, Cote RJ. Prognostic value of cell-cycle regulation biomarkers in bladder cancer. In Proceedings of the Seminars in oncology; Elsevier, 2012; Vol. 39, pp. 524-533.
[55] Li H-L, Zhang S, Wang Y, Liang R-R, Li J, An P, Wang Z-M, Yang J, Li Z-F. Baicalein induces apoptosis via a mitochondrial-dependent caspase activation pathway in T24 bladder cancer cells. Mol Med Rep. 2013;7:266-70.
[56] Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, Reddy GPV. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 2002;62:2488-92.
[57] Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2016;16:35-42.
[58] Oršolić N, Karač I, Sirovina D, Kukolj M, Kunštić M, Gajski G, Garaj-Vrhovac V, Štajcar D. Chemotherapeutic potential of quercetin on human bladder cancer cells. J Environ Sci Heal Part A. 2016;51:776-81.
[59] Baas IO, Mulder JR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant P53 gene product in archival colorectal neoplasms. J Pathol. 1994;172:5-12.
[60] Tian B, Wang Z, Zhao Y, Wang D, Li Y, Ma L, Li X, Li J, Xiao N, Tian J. Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett. 2008;264:299-308.
[61] Iida K, Naiki T, Naiki-Ito A, Suzuki S, Kato H, Nozaki S, Nagai T, Etani T, Nagayasu Y, Ando R, et al. Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway. Cancer Sci. 2020;111:1165-79. https://doi.org/10.1111/cas.14334.
[62] Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, Wu J, Xu X, Xu X, Qin J, Xie L. Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell Int. 2013;13:1-7. https://doi.org/10.1186/1475-2867-13-54.
[63] Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424.
[64] Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell death Differ. 1999;6:99-104.
[65] Morgensztern D, McLeod HL. PI3K/Akt/MTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797-803.
[66] Tsui K, Chiang K, Lin Y, Chang K, Feng T, Juang H. BTG2 is a tumor suppressor gene upregulated by P53 and PTEN in human bladder carcinoma cells. Cancer Med. 2018;7:184-95.
[67] Su H, Qiao X, Li T, Li C, Liu X, Ling H, Li X. Allicin suppressed bladder cancer cell biological activities via regulation of the MiR-26b-5p/PTEN axis in an in vitro study. Arch Med Sci. 2020; 16.
[68] Philips BJ, Coyle CH, Morrisroe SN, Chancellor MB, Yoshimura N. Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res. 2009;30:207-15.
[69] Bouffioux CR. Epidemiology of bladder cancer. Prog Clin Biol Res. 1984;162A:11-25. https://doi.org/10.17816/kazmj104542.
[70] Zhou C, Ding JUN, Wu Y. Resveratrol induces apoptosis of bladder cancer cells via MiR-21 regulation of the Akt/Bcl-2 signaling pathway. Mol Med Rep. 2014;9:1467-73.
[71] Wu M-L, Li H, Yu L-J, Chen X-Y, Kong Q-Y, Song X, Shu X-H, Liu J. Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS ONE. 2014;9: e89806.
[72] Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R III, Li X, Safe S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 2008;68:5345-54.
[73] Su Q, Peng M, Zhang Y, Xu W, Darko KO, Tao T, Huang Y, Tao X, Yang X. Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. Am J Cancer Res. 2016;6:498-508.
[74] Qingxin L, Xianggui C, Guolin Y, Xuewen M, Maoxian D. Apigenin inhibits cell migration through MAPK pathways in human bladder smooth muscle cells. Biocell. 2011;35:71-9.
[75] Tang L, Zhang Y. Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells. Mol Cancer Ther. 2005;4:1250-9.
[76] Abbaoui B, Telu KH, Lucas CR, Thomas-Ahner JM, Schwartz SJ, Clinton SK, Freitas MA, Mortazavi A. The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer. J Proteomics. 2017;156:94-103.
[77] Choi E-O, Park C, Hwang H-J, Hong SH, Kim G-Y, Cho E-J, Kim W-J, Choi YH. Baicalein induces apoptosis via ROS-dependent activation of caspases in human bladder cancer 5637 cells. Int J Oncol. 2016;49:1009-18.
[78] Zhang M, Du H, Huang Z, Zhang P, Yue Y, Wang W, Liu W, Zeng J, Ma J, Chen G. Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway. Chem Biol Interact. 2018;292:65-75.
[79] Zhang M, Du H, Wang L, Yue Y, Zhang P, Huang Z, Lv W, Ma J, Shao Q, Ma M. Thymoquinone suppresses invasion and metastasis in bladder cancer cells by reversing EMT through the Wnt/β-Catenin signaling pathway. Chem Biol Interact. 2020;320: 109022.
[80] Hou C-P, Tsui K-H, Chang K-S, Sung H-C, Hsu S-Y, Lin Y-H, Yang P-S, Chen C-L, Feng T-H, Juang H-H. Caffeic acid phenethyl ester inhibits the growth of bladder carcinoma cells by up-regulating growth differentiation factor 15. Biomed J. 2022;45:763-75.
[81] Borlinghaus J, Albrecht F, Gruhlke MCH, Nwachukwu ID, Slusarenko AJ. Allicin: chemistry and biological properties. Molecules. 2014;19:12591-618.
[82] Nagle DG, Ferreira D, Zhou Y-D. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006;67:1849-55.
[83] Sun H, Zhang T, Liu R, Cao W, Zhang Z, Liu Z, Qian W, Wang D, Yu D, Zhong C. Resveratrol inhibition of renal cancer stem cell characteristics and modulation of the sonic hedgehog pathway. Nutr Cancer. 2021;73:1157-67.
[84] Yang R, Zhang H, Zhu L. Inhibitory effect of resveratrol on the expression of the VEGF gene and proliferation in renal cancer cells. Mol Med Rep. 2011;4:981-3.
[85] Zhang H, Xu W, Li B, Zhang K, Wu Y, Xu H, Wang J, Zhang J, Fan R, Wei J. Curcumin promotes cell cycle arrest and inhibits survival of human renal cancer cells by negative modulation of the PI3K/AKT signaling pathway. Cell Biochem Biophys. 2015;73:681-6.
[86] Gao R, Ma Y, Wang Y, Xu H. Curcumin inhibits the proliferation of renal cancer 786-O cells through MTOR signaling pathway and its mechanism. J Healthcare Eng. 2022, 2022.
[87] Meng S, Zhu Y, Li J-F, Wang X, Liang Z, Li S-Q, Xu X, Chen H, Liu B, Zheng X-Y. Apigenin inhibits renal cell carcinoma cell proliferation. Oncotarget. 2017;8:19834.
[88] Bao Y, Wu X, Jin X, Kanematsu A, Nojima M, Kakehi Y, Yamamoto S. Apigenin inhibits renal cell carcinoma cell proliferation through G2/M phase cell cycle arrest. Oncol Rep. 2022;47:1-7.
[89] Jiang Z, Liu X, Chang K, Liu X, Xiong J. Allyl isothiocyanate inhibits the proliferation of renal carcinoma cell line GRC-1 by inducing an imbalance between Bcl2 and Bax. Med Sci Monit Int Med J Exp Clin Res. 2016;22:4283.
[90] Lee Y-M, Kim G-H, Park E-J, Oh T-I, Lee S, Kan S-Y, Kang H, Kim BM, Kim JH, Lim J-H. Thymoquinone selectively kills hypoxic renal cancer cells by suppressing HIF-1α-mediated glycolysis. Int J Mol Sci. 2019;20:1092.
[91] Chae IG, Song N-Y, Kim D-H, Lee M-Y, Park J-M, Chun K-S. Thymoquinone induces apoptosis of human renal carcinoma Caki-1 cells by inhibiting JAK2/STAT3 through pro-oxidant effect. Food Chem Toxicol. 2020;139: 111253.
[92] Sahin K, Cross B, Sahin N, Ciccone K, Suleiman S, Osunkoya AO, Master V, Harris W, Carthon B, Mohammad R. Lycopene in the prevention of renal cell cancer in the TSC2 mutant eker rat model. Arch Biochem Biophys. 2015;572:36-9.
[93] Jung JE, Kim HS, Lee CS, Park D-H, Kim Y-N, Lee M-J, Lee JW, Park J-W, Kim M-S, Ye SK. Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis. 2007;28:1780-7.
[94] Song B, Shu Y, Cui T, Fu P. Allicin inhibits human renal clear cell carcinoma progression via suppressing HIF pathway. Int J Clin Exp Med. 2015;8:20573.
[95] Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, Rybak LP, Ramkumar V. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS ONE. 2012;7: e51655.
[96] Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 2006;9:147-52.
[97] Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, Rhim JS. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol. 2002;21:825-30.
[98] Senthilkumar K, Arunkumar R, Elumalai P, Sharmila G, Gunadharini DN, Banudevi S, Krishnamoorthy G, Benson CS, Arunakaran J. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011;29:87-95.
[99] Tummala R, Lou W, Gao AC, Nadiminty N. Quercetin targets HnRNPA1 to overcome enzalutamide resistance in prostate cancer cellsquercetin targets HnRNPA1 and synergizes with enzalutamide. Mol Cancer Ther. 2017;16:2770-9.
[100] Shukla S, Bhaskaran N, Babcook MA, Fu P, MacLennan GT, Gupta S. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis. 2014;35:452-60.
[101] Shukla S, Fu P, Gupta S. Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer. Apoptosis. 2014;19:883-94.
[102] Bommareddy A, Hahm E-R, Xiao D, Powolny AA, Fisher AL, Jiang Y, Singh S. V Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res. 2009;69:3704-12.
[103] Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, Kim S-H, Hahm E-R, Normolle D, Van Houten B, Singh S. V Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem. 2010;285:26558-69.
[104] Kou B, Liu W, Zhao W, Duan P, Yang Y, Yi Q, Guo F, Li J, Zhou J, Kou Q. Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway. Oncol Rep. 2017;38:3592-8.
[105] Alshyarba M, Otifi H, AlFayi M, Dera A, Rajagopalan P. Thymoquinone inhibits IL-7-induced tumor progression and metastatic invasion in prostate cancer cells by attenuating matrix metalloproteinase activity and Akt/NF-κB signaling. Biotechnol Appl Biochem. 2021;68:1403-11.
[106] Lin H-P, Lin C-Y, Liu C-C, Su L-C, Huo C, Kuo Y-Y, Tseng J-C, Hsu J-M, Chen C-K, Chuu C-P. Caffeic acid phenethyl ester as a potential treatment for advanced prostate cancer targeting Akt signaling. Int J Mol Sci. 2013;14:5264-83.
[107] Thomas R, Kim MH. Epigallocatechin gallate inhibits HIF-1α degradation in prostate cancer cells. Biochem Biophys Res Commun. 2005;334:543-8.
[108] Zhou C, Zhao XM, Li XF, Wang C, Zhang XT, Liu XZ, Ding XF, Xiang SL, Zhang J. Curcumin inhibits AP-2Y-induced apoptosis in the human malignant testicular germ cells in vitro. Acta Pharmacol Sin. 2013;34:1192-200. https://doi.org/10.1038/aps.2013.38.
[109] Zhou C, Zhao X, Li X, Wang C, Zhang X, Liu X, Ding X, Xiang S, Zhang J. Curcumin inhibits AP-2γ-induced apoptosis in the human malignant testicular germ cells in vitro. Acta Pharmacol Sin. 2013;34:1192-200.
[110] Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37:219-25.
[111] Nakayama T, Kitano S. Immunotherapy for genitourinary tumors. Int J Urol. 2019;26:326-33.
[112] Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer, 2005. CA Cancer J Clin. 2005;55:31-44.
[113] Dellis A, Zagouri F, Liontos M, Mitropoulos D, Bamias A, Papatsoris AG, Group, H.G.-U.C. Management of advanced prostate cancer: a systematic review of existing guidelines and recommendations. Cancer Treat Rev. 2019;73:54-61.
[114] Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016;388:2796-810.
[115] Hisamura F, Kojima-Yuasa A, Huang X, Kennedy DO, Matsui-Yuasa I. Synergistic effect of green tea polyphenols on their protection against FK506-induced cytotoxicity in renal cells. Am J Chin Med. 2008;36:615-24. https://doi.org/10.1142/S0192415X08006028.
[116] Meng FD, Li Y, Tian X, Ma P, Sui CG, Fu LY, Jiang YH. Synergistic effects of snail and quercetin on renal cell carcinoma Caki-2 by altering AKT/MTOR/ERK1/2 signaling pathways. Int J Clin Exp Pathol. 2015;8:6157-68.
[117] Li W, Liu M, Xu YF, Feng Y, Che JP, Wang GC, Zheng JH. Combination of quercetin and hyperoside has anti-cancer effects on renal cancer cells through inhibition of oncogenic MicroRNA-27a. Oncol Rep. 2014;31:117-24. https://doi.org/10.3892/or.2013.2811.
[118] Sakamoto K. Synergistic effects of thearubigin and genistein on human prostate tumor cell (PC-3) growth via cell cycle arrest. Cancer Lett. 2000;151:103-9. https://doi.org/10.1016/S0304-3835(99)00423-1.
[119] Mei M, Twardowski P. Metastatic genitourinary malignancies. In: Madame Curie Bioscience Database [Internet]; Landes Bioscience, 2013.
[120] Vogelzang NJ. Future directions for gemcitabine in the treatment of genitourinary cancer. In: Proceedings of the Seminars in oncology; Elsevier, 2002; Vol. 29, pp. 40-45.
[121] Atkins MB, Larkin J. Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. JNCI J Natl Cancer Inst. 2016;108:djv414.
[122] Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer. 2006;4:257-62.
[123] Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol. 2017;10:1-12.
[124] Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96-108.
[125] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34. https://doi.org/10.3322/caac.21551.
[126] Mariotto AB, Noone A-M, Howlader N, Cho H, Keel GE, Garshell J, Woloshin S, Schwartz LM. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014:145-86.
[127] El-Achkar A, Souhami L, Kassouf W. Bladder preservation therapy: review of literature and future directions of trimodal therapy. Curr Urol Rep. 2018;19:1-10.
[128] Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12:211-4.
[129] Lattanzi M, Balar A. V current status and future direction of immunotherapy in urothelial carcinoma. Curr Oncol Rep. 2019;21:1-12.
[130] Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002;20:937-40.
[131] Godwin JL, Hoffman-Censits J, Plimack E. Recent developments in the treatment of advanced bladder cancer. In Proceedings of the Urologic Oncology: Seminars and Original Investigations; Elsevier, 2018; Vol. 36, pp. 109-114.
[132] Hermans TJN, van de Putte EEF, Horenblas S, Meijer RP, Boormans JL, Aben KKH, van der Heijden MS, de Wit R, Beerepoot LV, Verhoeven RHA. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—results of a Nationwide Population-Based Study. Eur J Cancer. 2016;69:1-8.
[133] Johnson SB, Yu JB. Bladder preserving trimodality therapy for muscle-invasive bladder cancer. Curr Oncol Rep. 2018;20:1-8.
[134] Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol. 2014;66:361-70.
[135] Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, Herr HW, Milowsky MI. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009;55:177-86.
[136] Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:1107.
[137] Williamson SR, Taneja K, Cheng L. Renal cell carcinoma staging: pitfalls, challenges, and updates. Histopathology. 2019;74:18-30.
[138] Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-96.
[139] Buonerba C, De Placido P, Bruzzese D, Pagliuca M, Ungaro P, Bosso D, Ribera D, Iaccarino S, Scafuri L, Liotti A, et al. Isoquercetin as an adjunct therapy in patients with kidney cancer receiving first-line sunitinib (QUASAR): results of a phase I trial. Front Pharmacol. 2018;9:189. https://doi.org/10.3389/fphar.2018.00189.
[140] Willenbacher E, Khan SZ, Mujica SCA, Trapani D, Hussain S, Wolf D, Willenbacher W, Spizzo G, Seeber A. Curcumin: new insights into an ancient ingredient against cancer. Int J Mol Sci. 2019;20:1-13. https://doi.org/10.3390/ijms20081808.
[141] NCT03211104 Comparison of Duration of Treatment Interruption With or Without Curcumin During the Off Treatment Periods in Patients With Prostate Cancer Undergoing Intermittent Androgen Deprivation Therapy. https://clinicaltrials.gov/show/NCT03211104 2017.
[142] NCT03769766 Trial of Curcumin to Prevent Progression of Low-Risk Prostate Cancer Under Active Surveillance. https://clinicaltrials.gov/show/NCT03769766 2018.
[143] Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 2010;5:61-74. https://doi.org/10.1007/s12263-009-0152-3. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
